美股新聞 標題聯播 · 近 24 小時 305 則 · 28 個來源 · 最新 9/20 06:00
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · VSTM近 30 天 4 則 · 第 1 / 1 頁
- Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
- Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
- Verastem Oncology to Participate in Upcoming September Investor Conferences
- Verastem (VSTM) Stock Sees Fair Value Moves Lower As Analysts Cut Revenue Views
- Verastem (VSTM) Q2 2026 Earnings Call Transcript
- Verastem Q2 Earnings Call Highlights
- Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong Revenue Rebound and Strategic ...
- Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates
- Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
- Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
- Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
- Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
- Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
- RBC Capital Reaffirms Outperform Rating For Verastem (VSTM)
- Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains?
- Here’s What RBC Capital Has to Say About Verastem (VSTM)
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Verastem (VSTM) Shares Encouraging Results from VS-7375 Phase 1/2 Trial
- Is Verastem, Inc. (VSTM)’s KRAS-Targeted Combination Therapy a Breakthrough for Pancreatic Cancer?
- Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。